SNIPR BIOME has announced the U.S. Food and Drug Administration (FDA) has approved their Investigational New Drug (IND) application for SNIPR001 to target E. coli infections in cancer patients. E. coli bacteria live in the intestines of healthy people and while most strains are harmless, certain strains such as E. coli 0157:H7, can lead to severe diarrhea, stomach pain, and kidney failure. The new therapy, SNIPR001, is designed to selectively target E. coli in patients with hematological malignancies, or cancers that affect the blood, bone marrow, and lymph nodes. In patients with hematological malignancies, E. coli infections present an increased risk for serious and life-threatening infections in the bloodstream. SNIPR001 is CRISPR-based treatment that is designed to target specific, potentially harmful strains of E. coli bacteria without damaging the patient’s microbiome. The company, SNIPR BIOME, is a biotechnology company that develops CRISPR-based therapies to target microbial pathogens.

Read more here.